Royalty Report: Medical, Diagnostic, Cancer – Collection: 26200


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Medical
  • Diagnostic
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26200

License Grant
The Licensor and the Licensee desire to collaborate on the commercialization of Thymira. Each of the parties shall use commercially reasonable efforts to achieve Commercialization on or before the first anniversary of the Effective Date.
License Property
The Licensor is a molecular diagnostics company focusing on predictive and prognostic genetic cytology and has the rights to the following diagnostic tests: ThymiraTM – a diagnostic test used to differentiate between benign and malignant ‘indeterminate’ thyroid FNA lesions comprised of 4 biomarkers that measure microRNA expression levels from a sample using fine needle aspiration; and ArmiraTM – a test to diagnose kidney transplant rejection by predicting acute rejection and renal allograft function.
Field of Use
THYMIRAâ„¢ is a molecular test for indeterminate thyroid nodules and ARMIRAâ„¢, a molecular test to determine and monitor acute kidney rejection.

The Licensee is a provider of outsourced commercial services to pharmaceutical, biotechnology and medical device clients in the United States and offers sales support services, clinical educator services, digital communications, tele-detailing and full-service product commercialization solutions.

IPSCIO Record ID: 28718

License Grant
The Company, through its wholly-owned subsidiary acquired miRInform® Thyroid and Pancreas cancer diagnostic tests, other tests in development for thyroid cancer, associated intellectual property and a biobank with more than 5,000 patient tissue samples from the Seller.
License Property
miRInform Thyroid is a Panel of molecular markers which improves preoperative diagnostic accuracy for patients with indeterminate thyroid nodules.

miRInform® Pancreas was developed to aid physicians in the diagnosis and management of pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive. The test evaluates expression levels of seven miRNAs in Fine Needle Aspirate (FNA) specimens of pancreatic masses.

IPSCIO Record ID: 26038

License Grant
The Licensor grants to Licensee a non-exclusive right and license, without the right to sublicense, under the Licensed Patent Rights as licensed to Licensor pursuant to the Original Agreement, to make, have made, use, sell, offer for sale and import Licensed Products and to practice the Licensed Methods in the Field in the Territory to the extent permitted by law.
License Property
The Licensor is involved in the discovery, development and commercialization of medical tests that diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. Field shall mean in-vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.
Field of Use
The Licensee is a provider of clinical laboratory services.

Field” shall mean in vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.